Patient demographics and clinical variables by dose level
| . | 100 mg (n = 6) . | 150 mg (n = 6) . | Total (N = 12) . |
|---|---|---|---|
| Median age (range), y | 62 (32-83) | 63 (48-68) | 63.5 (32-83) |
| Diagnosis, n (%) | |||
| ET | 1 (16.7) | 0 (0.0) | 1 (8.3) |
| PV | 5 (83.3) | 6 (100.0) | 11 (91.6) |
| Female sex, n (%) | 5 (83.3) | 2 (33.3) | 7 (58.3) |
| Median disease duration (range), mo | 41.6 (14.9-80.1) | 65.4 (21.0-154.3) | 43.9 (14.9-154.3) |
| Previous thrombosis, n (%) | 3 (50.0) | 0 (0.0) | 3 (25.0) |
| Prior hydroxyurea therapy, n (%) | 5 (83.3) | 5 (83.3) | 10 (83.3) |
| Median spleen length by palpation (range), cm | 1.0 (1.0-7.0) | 2.5 (0.0-18.0) | 1.0 (0.0-18.0) |
| Median leukocytes (range), ×109/L | 10.3 (4.9-15.9) | 12.2 (7.4-28.3) | 11.3 (4.9-28.3) |
| Median hemoglobin (range), g/dL | 13.4 (12.8-15.6) | 13.7 (12.3-14.7) | 13.6 (12.3-15.6) |
| Median hematocrit (range), % | 41.5 (38.3-46.7) | 43.0 (40.7-47.8) | 42.3 (38.3-47.8) |
| Median platelets (range), ×109/L | 443.5 (118.0-1339.0) | 412.0 (153.0-700.0) | 443.5 (118.0-1339.0) |
| Median LDH (range), U/L* | 252.0 (184.0-370.0) | 252.0 (177.0-616.0) | 252.0 (177.0-616.0) |
| Median JAK2 V617F VAF (range), % | 23.7 (5.3-69.3) | 63.7 (6.3-88.6) | 40.6 (5.3-88.6) |
| . | 100 mg (n = 6) . | 150 mg (n = 6) . | Total (N = 12) . |
|---|---|---|---|
| Median age (range), y | 62 (32-83) | 63 (48-68) | 63.5 (32-83) |
| Diagnosis, n (%) | |||
| ET | 1 (16.7) | 0 (0.0) | 1 (8.3) |
| PV | 5 (83.3) | 6 (100.0) | 11 (91.6) |
| Female sex, n (%) | 5 (83.3) | 2 (33.3) | 7 (58.3) |
| Median disease duration (range), mo | 41.6 (14.9-80.1) | 65.4 (21.0-154.3) | 43.9 (14.9-154.3) |
| Previous thrombosis, n (%) | 3 (50.0) | 0 (0.0) | 3 (25.0) |
| Prior hydroxyurea therapy, n (%) | 5 (83.3) | 5 (83.3) | 10 (83.3) |
| Median spleen length by palpation (range), cm | 1.0 (1.0-7.0) | 2.5 (0.0-18.0) | 1.0 (0.0-18.0) |
| Median leukocytes (range), ×109/L | 10.3 (4.9-15.9) | 12.2 (7.4-28.3) | 11.3 (4.9-28.3) |
| Median hemoglobin (range), g/dL | 13.4 (12.8-15.6) | 13.7 (12.3-14.7) | 13.6 (12.3-15.6) |
| Median hematocrit (range), % | 41.5 (38.3-46.7) | 43.0 (40.7-47.8) | 42.3 (38.3-47.8) |
| Median platelets (range), ×109/L | 443.5 (118.0-1339.0) | 412.0 (153.0-700.0) | 443.5 (118.0-1339.0) |
| Median LDH (range), U/L* | 252.0 (184.0-370.0) | 252.0 (177.0-616.0) | 252.0 (177.0-616.0) |
| Median JAK2 V617F VAF (range), % | 23.7 (5.3-69.3) | 63.7 (6.3-88.6) | 40.6 (5.3-88.6) |
LDH, lactate dehydrogenase. Upper limit of normal for LDH is 220 U/L.